1217649-53-0

Basic information

• Product Name: (S)-N₁-((2S,3R)-4-((3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl)-3-hydroxy-1-(4-phenylthiophen-2-yl)butan-2-yl)-2-(quinoline-2-carboxamido)succinamide
• CAS NO: 1217649-53-0
• Molecular Weight: 752.978
• Mol File: 1217649-53-0.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (S)-N₁-((2S,3R)-4-((3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl)-3-hydroxy-1-(4-phenylthiophen-2-yl)butan-2-yl)-2-(quinoline-2-carboxamido)succinamide(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-N₁-((2S,3R)-4-((3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl)-3-hydroxy-1-(4-phenylthiophen-2-yl)butan-2-yl)-2-(quinoline-2-carboxamido)succinamide(1217649-53-0)
• EPA Substance Registry System: (S)-N₁-((2S,3R)-4-((3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl)-3-hydroxy-1-(4-phenylthiophen-2-yl)butan-2-yl)-2-(quinoline-2-carboxamido)succinamide(1217649-53-0)

Safety Data

• Hazardous Substances Data: 1217649-53-0(Hazardous Substances Data)

Upstream product

• 1208246-92-7 (3S,4aS,8aS)-2-((2R,3S)-3-amino-2-hydroxy-4-(4-phenylthiophen-2-yl)butyl)-N-tertbutyldecahydroisoquinoline-3-carboxamide 
• 136465-98-0 (2S)-2-[(quinoline-2-carbonyl)-amino]-succinamic acid 

Relevant articles and documents

Synthesis of new thienyl ring containing HIV-1 protease inhibitors: Promising preliminary pharmacological evaluation against recombinant HIV-1 proteases

A series of new thienyl ring containing analogues of nelfinavir and saquinavir with different, substitution patterns were synthesized from suitable enantiopure diols. Their inhibitory activity against wild type recombinant HIV-1 protease was evaluated. In general thienyl groups spaced from the core by a methylene group gave products showing IC50 in the nanomolar range, irrespective of the type and the substitution pattern of the heterocycle. The range of activity of the two most, active compounds is substantially maintained or even increased against two commonly selected mutants, under drug pressure, such as V32I and V82A.